A daily glass of cloudy apple juice may decrease body fat in obese people, compared to a control beverage, with greater effects noted in individuals with certain genetic profiles. Four weeks of drinking 750 mL per day glass of cloudy apple juice providing 802.5 mg polyphenols were associated with a …

A new position statement for treatment of type 2 diabetes treatment focuses on the individual patient rather than a "one number fits all" HbA1c target….

Higher levels of leisure-time physical activity cut the risk of cardiovascular and all-cause mortality in people with type 2 diabetes….

Continuous long-term delivery of exenatide with Intarcia’s osmotic mini-pump system allows optimal dose selection for improved glycemic control, ensures adherence, and improves patient tolerability….

Merck announced Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes…. 

Researchers report that, for type 1 diabetes patients who have good glycemic control, renal function may predict their risk of developing heart disease….

Analysis demonstrated reductions in systolic blood pressure with empagliflozin, an investigational SGLT-2 inhibitor, independent of changes in blood glucose and weight in adults with type 2 diabetes…. Boehringer Ingelheim and Eli Lilly announced data from a pooled analysis of two phase IIb trials in adults with type 2 diabetes (T2D) …

First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease…. Canagliflozin was also shown to be effective and generally well-tolerated in patients with type 2 diabetes aged 55 to …

Researchers have identified a mitochondrial target through which insulin sensitizers achieve their anti-diabetic effects…. 

Eli Lilly and Boehringer Ingelheim announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes….